| User's Publication |
|
20104
Abe K, Kanehira M, Ohkouchi S, Kumata S, Suzuki Y, Oishi H, Noda M, Sakurada A, Miyauchi E, Fujiwara T, Harigae H, Okada Y.
Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer.
Cancer Med
2021
PubMed ID: 33826244
|
|
7054
Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S.
Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer.
J Thorac Oncol
2020
15(5):752-765
PubMed ID: 31972351
|
|
11955
Ren T, Fan XX, Wang MF, Duan FG, Wei CL, Li RZ, Jiang ZB, Wang YW, Yao XJ, Chen MW, Tang YJ, Leung EL.
miR‑20b promotes growth of non‑small cell lung cancer through a positive feedback loop of the Wnt/β‑catenin signaling pathway.
Int. J. Oncol.
2020
PubMed ID: 31894264
|
|
12050
Azuma Y, Yokobori T, Mogi A, Yajima T, Kosaka T, Iijima M, Shimizu K, Shirabe K, Kuwano H.
Cancer exosomal microRNAs from gefitinib-resistant lung cancer cells cause therapeutic resistance in gefitinib-sensitive cells.
Surg. Today
2020
PubMed ID: 32052182
|
|
12085
Lin Y, Higashisaka K, Shintani T, Maki A, Hanamuro S, Haga Y, Maeda S, Tsujino H, Nagano K, Fujio Y, Tsutsumi Y.
Progesterone receptor membrane component 1 leads to erlotinib resistance, initiating crosstalk of Wnt/β-catenin and NF-κB pathways, in lung adenocarcinoma cells.
Sci Rep
2020
PubMed ID: 32179851
|
|
12089
Tanaka H, Hino H, Moriya S, Kazama H, Miyazaki M, Takano N, Hiramoto M, Tsukahara K, Miyazawa K.
Comparison of autophagy inducibility in various tyrosine kinase inhibitors and their enhanced cytotoxicity via inhibition of autophagy in cancer cells in combined treatment with azithromycin.
Biochem Biophys Rep
2020
PubMed ID: 32195376
|
|
13153
Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C.
Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing.
Biomedicines
2020
PubMed ID: 32764319
|
|
13224
Wang R, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W, Suzuki T, Yano S.
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Nat Commun
2020
PubMed ID: 32929081
|
|
13283
Arai S, Takeuchi S, Fukuda K, Tanimoto A, Nishiyama A, Konishi H, Takagi A, Takahashi H, Ong ST, Yano S.
Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
J Med Invest
2020
PubMed ID: 33148913
|
|
13543
Okuno D, Sugiura Y, Sakamoto N, Tagod MSO, Iwasaki M, Noda S, Tamura A, Senju H, Umeyama Y, Yamaguchi H, Suematsu M, Morita CT, Tanaka Y, Mukae H.
Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells
Front Immunol
2020
11:1405
PubMed ID: 32793196
|
|
11336
Kosibaty Z, Murata Y, Minami Y, Dai T, Kano J, Matsuoka R, Nakano N, Noguchi M.
Cytoplasmic expression of epithelial cell transforming sequence 2 in lung adenocarcinoma and its implications for malignant progression.
Lab. Invest.
2019
PubMed ID: 30542068
|
|
11372
Sun Y, Bandi M, Lofton T, Smith M, Bristow CA, Carugo A, Rogers N, Leonard P, Chang Q, Mullinax R, Han J, Shi X, Seth S, Meyers BA, Miller M, Miao L, Ma X, Feng N, Giuliani V, Geck Do M, Czako B, Palmer WS, Mseeh F, Asara JM, Jiang Y, Morlacchi P, Zhao S, Peoples M, Tieu TN, Warmoes MO, Lorenzi PL, Muller FL, DePinho RA, Draetta GF, Toniatti C, Jones P, Heffernan TP, Marszalek JR.
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation.
Cell Rep
2019
PubMed ID: 30625329
|
|
11384
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Nat Commun
2019
PubMed ID: 30651547
|
|
11421
Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N.
Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts.
J. Cell. Mol. Med.
2019
PubMed ID: 30734495
|
|
11453
Kobayashi M, Saito R, Miki Y, Nanamiya R, Inoue C, Abe J, Sato I, Okada Y, Sasano H.
The correlation of p22phox and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma.
Oncotarget
2019
PubMed ID: 30800222
|
|
11461
Imabayashi T, Uchino J, Osoreda H, Tanimura K, Chihara Y, Tamiya N, Kaneko Y, Yamada T, Takayama K.
Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients.
Cancers (Basel)
2019
PubMed ID: 30818860
|
|
11746
Mizutani K, Guo X, Shioya A, Zhang J, Zheng J, Kurose N, Ishibashi H, Motono N, Uramoto H, Yamada S.
The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Int J Med Sci
2019
PubMed ID: 31588184
|
|
11808
Sanomachi T, Suzuki S, Togashi K, Seino S, Yoshioka T, Kitanaka C, Okada M, Yamamoto M.
Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer.
Anticancer Res.
2019
PubMed ID: 31519584
|
|
11848
Sanomachi T, Suzuki S, Togashi K, Sugai A, Seino S, Okada M, Yoshioka T, Kitanaka C, Yamamoto M.
Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs.
Cancers (Basel)
2019
PubMed ID: 31614999
|
|
6892
Okita R, Maeda A, Shimizu K, Nojima Y, Saisho S, Nakata M.
Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Oncol Rep
2019
42(2):839-848
PubMed ID: 31173242
|
|
12553
Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, Chen T, Yang J, Jing M, Chen F, Wang C, Sun H, Huang Y.
EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis
Int J Oncol
2019
54(1):370-380
PubMed ID: 30431083
|
|
10633
Asaka S, Yoshizawa A, Nakata R, Negishi T, Yamamoto H, Shiina T, Shigeto S, Matsuda K, Kobayashi Y, Honda T.
Utility of bronchial lavage fluids for epithelial growth factor receptor mutation assay in lung cancer patients: Comparison between cell pellets, cell blocks and matching tissue specimens.
Oncol Lett
2018
15:1469-1474
PubMed ID: 29399190
|
|
10679
Yoneda K, Chikaishi Y, Kuwata T, Ohnaga T, Tanaka F.
Capture of mesothelioma cells with 'universal' CTC-chip.
Oncol Lett
2018
15:2635-2640
PubMed ID: 29434985
|
|
10706
Bao H, Bai T, Takata K, Yokobori T, Ohnaga T, Hisada T, Maeno T, Bao P, Yoshida T, Kumakura Y, Honjo H, Sakai M, Sohda M, Fukuchi M, Altan B, Handa T, Ide M, Miyazaki T, Ogata K, Oyama T, Shimizu K, Mogi A, Asao T, Shirabe K, Kuwano H, Kaira K.
High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab.
Oncol Lett
2018
15:3061-3067
PubMed ID: 29435038
|
|
10721
Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.
Oncogenesis
2018
7:11
PubMed ID: 29362358
|
|
10768
Kashima Y, Suzuki A, Liu Y, Hosokawa M, Matsunaga H, Shirai M, Arikawa K, Sugano S, Kohno T, Takeyama H, Tsuchihara K, Suzuki Y.
Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response.
Sci Rep
2018
8:3482
PubMed ID: 29472726
|
|
10784
Senju H, Kumagai A, Nakamura Y, Yamaguchi H, Nakatomi K, Fukami S, Shiraishi K, Harada Y, Nakamura M, Okamura H, Tanaka Y, Mukae H.
Effect of IL-18 on the Expansion and Phenotype of Human Natural Killer Cells: Application to Cancer Immunotherapy.
Int. J. Biol. Sci.
2018
14:331-340
PubMed ID: 29559850
|
|
10785
Torigoe H, Yamamoto H, Sakaguchi M, Youyi C, Namba K, Sato H, Shien K, Soh J, Suzawa K, Tomida S, Tsukuda K, Miyoshi S, Toyooka S.
Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
Carcinogenesis
2018
39:719-727
PubMed ID: 29546323
|
|
11038
Saito R, Miki Y, Ishida N, Inoue C, Kobayashi M, Hata S, Yamada-Okabe H, Okada Y, Sasano H.
The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting
Int J Mol Sci
2018
19. pii: E609
PubMed ID: 29463039
|
|
11201
Cao S, Wang Z, Gao X, He W, Cai Y, Chen H, Xu R.
FOXC1 induces cancer stem cell-like properties through upregulation of beta-catenin in NSCLC.
J. Exp. Clin. Cancer Res.
2018
PubMed ID: 30189871
|
|
11307
Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S.
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.
Cell Stem Cell
2018
PubMed ID: 30449714
|
|
4141
Suzuki S, Okada M, Takeda H, Kuramoto K, Sanomachi T, Togashi K, Seino S, Yamamoto M, Yoshioka T, Kitanaka C.
Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells.
Oncotarget
2018
PubMed ID: 30220973
|
|
4320
Takeuchi M, Doi T, Obayashi K, Hirai A, Yoneda K, Tanaka F, Iwai Y.
Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Immunol. Lett.
2018
PubMed ID: 29366663
|
|
4321
Shintani T, Higashisaka K, Maeda M, Hamada M, Tsuji R, Kurihara K, Kashiwagi Y, Sato A, Obana M, Yamamoto A, Kawasaki K, Lin Y, Kijima T, Kinehara Y, Miwa Y, Maeda S, Morii E, Kumanogoh A, Tsutsumi Y, Nagatomo I, Fujio Y.
Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer.
Oncotarget
2018
PubMed ID: 30680067
|
|
10132
Liu Z, Yanagisawa K, Griesing S, Iwai M, Kano K, Hotta N, Kajino T, Suzuki M, Takahashi T.
TTF-1/NKX2-1 binds to DDB1 and confers replication stress resistance to lung adenocarcinomas.
Oncogene
2017
36:3740-3748
PubMed ID: 28192407
|
|
10280
Seike M, Kim CH, Zou F, Noro R, Chiba M, Ishikawa A, Κunugi S, Kubota K, Gemma A.
AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
Oncol. Rep.
2017
37:3261-3269
PubMed ID: 28440492
|
|
10317
Kurimoto R, Ebata T, Iwasawa S, Ishiwata T, Tada Y, Tatsumi K, Takiguchi Y.
Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma.
Oncol Lett
2017
14:944-950
PubMed ID: 28693256
|
|
10530
Niessen S, Dix MM, Barbas S, Potter ZE, Lu S, Brodsky O, Planken S, Behenna D, Almaden C, Gajiwala KS, Ryan K, Ferre R, Lazear MR, Hayward MM, Kath JC, Cravatt BF.
Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors.
Cell Chem Biol
2017
24:1388-1400.e7
PubMed ID: 28965727
|
|
13708
Griesing S, Kajino T, Tai MC, Liu Z, Nakatochi M, Shimada Y, Suzuki M, Takahashi T.
Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells
Cancer Sci
2017
108(7):1394-1404
PubMed ID: 28474808
|
|
7069
Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S.
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Nature
2016
534:402-6
PubMed ID: 27281199
|
|
9511
Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J, Hotta N, Shimada Y, Isomura H, Suzuki M, Fujimoto T, Takahashi T.
ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1.
Nat Commun
2016
7:10060
PubMed ID: 26725982
|
|
9598
Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A, Takiguchi Y.
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
Int. J. Oncol.
2016
48:1825-36
PubMed ID: 26984042
|
|
9731
Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O.
Establishment of anti-mesothelioma monoclonal antibodies.
BMC Res Notes
2016
9:324
PubMed ID: 27342200
|
|
9884
Watarai H, Okada M, Kuramoto K, Takeda H, Sakaki H, Suzuki S, Seino S, Oizumi H, Sadahiro M, Kitanaka C.
Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin.
Anticancer Res.
2016
36:6083-6092
PubMed ID: 27793936
|
|
10010
Koh V, Kwan HY, Tan WL, Mah TL, Yong WP.
Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells.
BMC Genomics
2016
17:1029
PubMed ID: 28155658
|
|
12883
Ida L, Yamaguchi T, Yanagisawa K, Kajino T, Shimada Y, Suzuki M, Takahashi T.
Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma
Cancer Sci
2016
107(2):155–161
PubMed ID: 26661061
|
|
7103
Greig MJ, Niessen S, Weinrich SL, Feng JL, Shi M, Johnson TO.
Effects of Activating Mutations on EGFR Cellular Protein Turnover and Amino Acid Recycling Determined Using SILAC Mass Spectrometry.
Int J Cell Biol
2015
2015:798936
PubMed ID: 26689952
|
|
7346
Yen HY, Liu YC, Chen NY, Tsai CF, Wang YT, Chen YJ, Hsu TL, Yang PC, Wong CH.
Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition.
Proc. Natl. Acad. Sci. U.S.A.
2015
112:6955-60
PubMed ID: 25971727
|
|
7402
Sugita S, Ito K, Yamashiro Y, Moriya S, Che XF, Yokoyama T, Hiramoto M, Miyazawa K.
EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells.
Biochem. Biophys. Res. Commun.
2015
461:28-34
PubMed ID: 25858318
|
|
7498
Sakamoto T, Kodani M, Takata M, Chikumi H, Nakamoto M, Nishii-Ito S, Ueda Y, Izumi H, Makino H, Touge H, Takeda K, Yamasaki A, Yanai M, Tanaka N, Igishi T, Shimizu E.
A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.
Int. J. Oncol.
2015
46:1473-80
PubMed ID: 25651992
|
|
7523
Elza C. de Bruin, Ming Jiang, Michael Howell, Julian Downward
Genome-Wide siRNA Screen for Anti-Cancer Drug Resistance in Adherent Cell Lines.
Bio-protocol
2015
5:e1474
|
Back
Top
CELL BANK Website
